Family history and breast cancer hormone receptor status in a Spanish cohort

PLoS One. 2012;7(1):e29459. doi: 10.1371/journal.pone.0029459. Epub 2012 Jan 6.

Abstract

Background: Breast cancer is a heterogenous disease that impacts racial/ethnic groups differently. Differences in genetic composition, lifestyles, reproductive factors, or environmental exposures may contribute to the differential presentation of breast cancer among Hispanic women.

Materials and methods: A population-based study was conducted in the city of Santiago de Compostela, Spain. A total of 645 women diagnosed with operable invasive breast cancer between 1992 and 2005 participated in the study. Data on demographics, breast cancer risk factors, and clinico-pathological characteristics of the tumors were collected. Hormone receptor negative tumors were compared with hormone receptor postive tumors on their clinico-pathological characteristics as well as risk factor profiles.

Results: Among the 645 breast cancer patients, 78% were estrogen receptor-positive (ER+) or progesterone receptor-positive (PR+), and 22% were ER-&PR-. Women with a family history of breast cancer were more likely to have ER-&PR- tumors than women without a family history (Odds ratio, 1.43; 95% confidence interval, 0.91-2.26). This association was limited to cancers diagnosed before age 50 (Odds ratio, 2.79; 95% confidence interval, 1.34-5.81).

Conclusions: An increased proportion of ER-&PR- breast cancer was observed among younger Spanish women with a family history of the disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Breast Neoplasms / ethnology
  • Breast Neoplasms / etiology
  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / pathology
  • Carcinoma / ethnology
  • Carcinoma / etiology
  • Carcinoma / metabolism*
  • Carcinoma / pathology
  • Cohort Studies
  • Disease Susceptibility
  • Family Health* / statistics & numerical data
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Staging
  • Receptors, Cytoplasmic and Nuclear / metabolism*
  • Risk Factors
  • Spain

Substances

  • Receptors, Cytoplasmic and Nuclear